Janelle F Ruisinger1, Cheryl A Gibson2, James M Backes3, Bryan K Smith4, Debra K Sullivan5, Patrick M Moriarty6, Penny Kris-Etherton7. 1. Department of Pharmacy Practice, University of Kansas School of Pharmacy, Kansas City, KS, USA. Electronic address: jruisinger@kumc.edu. 2. Department of Internal Medicine, Division of General and Geriatric Medicine, University of Kansas Medical Center, Kansas City, KS, USA. 3. Department of Pharmacy Practice, University of Kansas School of Pharmacy, Kansas City, KS, USA. 4. Department of Kinesiology and Health Education, Southern Illinois University Edwardsville, Vadalabene Center, Edwardsville, IL, USA. 5. Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA. 6. Department of Medicine, Division of Clinical Pharmacology, University of Kansas Medical Center, Atherosclerosis and LDL-Apheresis Center, Kansas City, KS, USA. 7. Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.
Abstract
BACKGROUND: Dietary supplementation with almonds has demonstrated dose-dependent decreases in low-density lipoprotein cholesterol (LDL-C), likely because of their composition of beneficial nutrients including mono- and polyunsaturated fatty acids, fiber, and protein. OBJECTIVE: The primary objective of this study was to determine the changes in the lipid profile (LDL-C, high-density lipoprotein cholesterol [HDL-C], triglycerides, total cholesterol, non-HDL-C), LDL-C particle size, and lipoprotein (a) when 100 g of almonds daily were added to background statin therapy for 4 weeks. METHODS:Subjects (N = 48) receiving aconsistent statin dose were randomized to 100 g of almonds daily and to The National Cholesterol Education Program Adult Treatment Panel's third report Therapeutic Lifestyle Changes Diet counseling (almond group; n = 22) or solely Adult Treatment Panel's third report Therapeutic Lifestyle Changes Diet counseling (non-almond group; n = 26), for 4 weeks. RESULTS: No significant changes in weight and weekly physical activity were noted between the 2 groups from baseline. However, the almond group consumed significantly more calories at 4 weeks compared with controls. The almond group experienced a 4.9% reduction in non-HDL-C compared with a 3.5% increase for the non-almond group (P = .02). Additionally, notable improvements were observed in LDL-C and triglycerides, but did not achieve statistical significance (P = .068 for both parameters). There was also a shift from LDL pattern A to pattern B particles (P = .003) in the almond group. No significant differences in total cholesterol (P = .1), HDL-C (P = .3), or lipoprotein (a) (P = .1) were observed. CONCLUSION: Adding 100 g of almonds daily to chronic statin therapy for 4 weeks significantly reduced non-HDL-C. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00603876.
RCT Entities:
BACKGROUND: Dietary supplementation with almonds has demonstrated dose-dependent decreases in low-density lipoprotein cholesterol (LDL-C), likely because of their composition of beneficial nutrients including mono- and polyunsaturated fatty acids, fiber, and protein. OBJECTIVE: The primary objective of this study was to determine the changes in the lipid profile (LDL-C, high-density lipoprotein cholesterol [HDL-C], triglycerides, total cholesterol, non-HDL-C), LDL-C particle size, and lipoprotein (a) when 100 g of almonds daily were added to background statin therapy for 4 weeks. METHODS: Subjects (N = 48) receiving a consistent statin dose were randomized to 100 g of almonds daily and to The National Cholesterol Education Program Adult Treatment Panel's third report Therapeutic Lifestyle Changes Diet counseling (almond group; n = 22) or solely Adult Treatment Panel's third report Therapeutic Lifestyle Changes Diet counseling (non-almond group; n = 26), for 4 weeks. RESULTS: No significant changes in weight and weekly physical activity were noted between the 2 groups from baseline. However, the almond group consumed significantly more calories at 4 weeks compared with controls. The almond group experienced a 4.9% reduction in non-HDL-C compared with a 3.5% increase for the non-almond group (P = .02). Additionally, notable improvements were observed in LDL-C and triglycerides, but did not achieve statistical significance (P = .068 for both parameters). There was also a shift from LDL pattern A to pattern B particles (P = .003) in the almond group. No significant differences in total cholesterol (P = .1), HDL-C (P = .3), or lipoprotein (a) (P = .1) were observed. CONCLUSION: Adding 100 g of almonds daily to chronic statin therapy for 4 weeks significantly reduced non-HDL-C. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00603876.
Authors: Stephanie K Nishi; Effie Viguiliouk; Sonia Blanco Mejia; Cyril W C Kendall; Richard P Bazinet; Anthony J Hanley; Elena M Comelli; Jordi Salas Salvadó; David J A Jenkins; John L Sievenpiper Journal: Obes Rev Date: 2021-09-08 Impact factor: 10.867